Aspiriant LLC Lowers Holdings in DocuSign, Inc. (NASDAQ:DOCU)

Aspiriant LLC decreased its stake in DocuSign, Inc. (NASDAQ:DOCU) by 4.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,102 shares of the company’s stock after selling 447 shares during the period. Aspiriant LLC’s holdings in DocuSign were worth $909,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in DOCU. KBC Group NV increased its holdings in shares of DocuSign by 209.8% in the 3rd quarter. KBC Group NV now owns 1,156,874 shares of the company’s stock worth $71,830,000 after buying an additional 783,419 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec grew its holdings in shares of DocuSign by 42.4% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 1,459,580 shares of the company’s stock valued at $90,625,000 after purchasing an additional 434,312 shares during the last quarter. International Assets Investment Management LLC grew its holdings in shares of DocuSign by 5,660.8% during the 3rd quarter. International Assets Investment Management LLC now owns 438,914 shares of the company’s stock valued at $27,252,000 after purchasing an additional 431,295 shares during the last quarter. FMR LLC grew its holdings in shares of DocuSign by 16.8% during the 3rd quarter. FMR LLC now owns 2,192,885 shares of the company’s stock valued at $136,156,000 after purchasing an additional 315,073 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in DocuSign during the 2nd quarter valued at $16,248,000. Institutional investors own 77.64% of the company’s stock.

Insider Buying and Selling at DocuSign

In other news, Director Daniel D. Springer sold 581,588 shares of DocuSign stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $97.04, for a total value of $56,437,299.52. Following the completion of the sale, the director now directly owns 906,430 shares in the company, valued at $87,959,967.20. The trade was a 39.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Robert Chatwani sold 14,800 shares of DocuSign stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $97.76, for a total transaction of $1,446,848.00. Following the completion of the sale, the insider now owns 73,414 shares of the company’s stock, valued at $7,176,952.64. This represents a 16.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 693,537 shares of company stock worth $66,575,817. 1.66% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

DOCU has been the subject of several analyst reports. Royal Bank of Canada reissued a “sector perform” rating and set a $90.00 price target (up previously from $57.00) on shares of DocuSign in a research report on Friday, December 6th. Robert W. Baird increased their price target on shares of DocuSign from $59.00 to $100.00 and gave the company a “neutral” rating in a research report on Friday, December 6th. UBS Group increased their price target on shares of DocuSign from $60.00 to $100.00 and gave the company a “neutral” rating in a research report on Friday, December 6th. Piper Sandler increased their price target on shares of DocuSign from $60.00 to $90.00 and gave the company a “neutral” rating in a research report on Friday, December 6th. Finally, Citigroup raised their target price on shares of DocuSign from $87.00 to $113.00 and gave the stock a “buy” rating in a research report on Friday, December 6th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $92.45.

DocuSign Stock Performance

NASDAQ:DOCU opened at $89.60 on Tuesday. The firm has a market cap of $18.10 billion, a P/E ratio of 18.47, a P/E/G ratio of 8.10 and a beta of 0.88. DocuSign, Inc. has a fifty-two week low of $48.70 and a fifty-two week high of $107.86. The firm has a 50-day simple moving average of $88.76 and a two-hundred day simple moving average of $70.38.

About DocuSign

DocuSign, Inc provides electronic signature solution in the United States and internationally. The company provides e-signature solution that enables sending and signing of agreements on various devices; Contract Lifecycle Management (CLM), which automates workflows across the entire agreement process; Document Generation streamlines the process of generating new, custom agreements; and Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce.